M&A / Deals Lilly puts up to $2.75bn into Insilico alliance PharmaphorumInsilico has once again added to its roster of big pharma partners, signing a deal with Eli Lilly that includes a $115m upfront payment.M&A / DealsRead full story pharminent March 29, 2026 (Last updated: March 30, 2026) Pharmaphorum Insilico has once again added to its roster of big pharma partners, signing a deal with Eli Lilly that includes a $115m upfront payment. M&A / DealsRead full story Post navigation Previous: S16 Ep38: Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLCNext: Otsuka grows in neuroplastogens with $1.225bn Transcend buy Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026